| Physiological relevance |
Highest — native gene expression, morphology, and signalling |
Reduced — genetic drift from immortalization, such as SV40 or hTERT |
Moderate — native background with a defined engineered target |
High for target lineage, but may reflect a fetal or immature phenotype |
Reflects malignant, not normal, physiology |
| Replicative lifespan |
Finite; senescence after limited passages |
Unlimited |
Unlimited |
Unlimited as stem cells; differentiated progeny is often finite |
Unlimited |
| Lot-to-lot / donor consistency |
Variable — donor-dependent factors can include age, sex, and health status |
High — clonal, homogeneous |
High — clonal, homogeneous |
High once a validated iPSC or ESC line is established |
High — clonal, but genetically unstable over passage |
| Genetic stability over passage |
Stable within the recommended passage window |
Can drift with extended culture |
Engineered locus is stable; background can still drift |
Karyotypic changes are possible with prolonged culture |
Frequently unstable or aneuploid |
| Ease of transfection / gene editing |
Often low; may need optimized or nucleofection reagents |
Generally high |
Not applicable — modification is already built in |
Moderate to high, protocol-dependent |
Generally high |
| Turnaround / scalability |
Limited by donor tissue supply and finite expansion |
High — expands indefinitely |
High — expands indefinitely and is ready to use |
High once a differentiation protocol is established, which can be lengthy |
High — expands indefinitely |
| Best-fit use cases |
Disease modelling, toxicology, immunology, ex vivo drug response |
Mechanistic studies, assay development, protein production |
Target validation, HTS, receptor pharmacology for GPCR, kinase, and ion channel targets |
Developmental biology and disease modelling from patient-derived iPSCs |
Oncology drug screening and tumour biology |